New hope to stop HIV passing from mom to baby
NCT ID NCT02245022
Summary
This study tested a newer HIV medication called dolutegravir in pregnant women who were diagnosed late in pregnancy. The goal was to see if the drug was safe for both mother and baby, how it moved through their bodies, and if it could quickly lower the mother's virus levels to help prevent passing HIV to the infant during birth. It compared the new drug to the standard HIV medications used during pregnancy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Desmond Tutu HIV Foundation
Cape Town, Western Cape, South Africa
-
Infectious Diseases Institute
Kampala, Uganda
Conditions
Explore the condition pages connected to this study.